Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis
Rik J.U. Lories, … , Inge Derese, Frank P. Luyten
Rik J.U. Lories, … , Inge Derese, Frank P. Luyten
Published June 1, 2005
Citation Information: J Clin Invest. 2005;115(6):1571-1579. https://doi.org/10.1172/JCI23738.
View: Text | PDF
Research Article Bone Biology

Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis

  • Text
  • PDF
Abstract

Joint ankylosis is a major cause of disability in the human spondyloarthropathies. Here we report that this process partially recapitulates embryonic endochondral bone formation in a spontaneous model of arthritis in DBA/1 mice. Bone morphogenetic protein (BMP) signaling appears to be a key molecular pathway involved in this pathological cascade. Systemic gene transfer of noggin, a BMP antagonist, is effective both as a preventive and a therapeutic strategy in the mouse model, mechanistically interfering with enthesial progenitor cell proliferation in early stages of the disease process. Immunohistochemical staining for phosphorylated smad1/5 in enthesial biopsies of patients with spondyloarthropathy reveals active BMP signaling in similar target cells. Our data suggest that BMP signaling is an attractive therapeutic target for interfering with structural changes in spondyloarthropathy either as an alternative or complementary approach to current antiinflammatory treatments.

Authors

Rik J.U. Lories, Inge Derese, Frank P. Luyten

×

Figure 7

Options: View larger image (or click on image) Download as PowerPoint
BMP signaling in human enthesitis in spondyloarthropathy. (A) X-ray imag...
BMP signaling in human enthesitis in spondyloarthropathy. (A) X-ray image showing irregular borders and bony outgrowth (arrows) at the Achilles enthesis. (B) Overview of an enthesial biopsy stained with H&E, showing a normal attachment zone (arrowheads) and new tissue formation (boxed area). (C) Detail of boxed area in B showing proliferation (arrowheads) and cartilage formation (arrows). (D) Immunofluorescent staining for phosphorylated-smad1/5/8 showing positive proliferating cells (arrowheads, detail in inset) and negative chondrocytes (arrows). (E–G) Double immunofluorescence for phosphorylated-smad1/5 (E), PCNA (F), and overlay (G). Scale bars: B, 800 μm; C and D, 200 μm; E and G, 50 μm.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts